Dissemin is shutting down on January 1st, 2025

Published in

Future Medicine, Pharmacogenomics, 14(13), p. 1635-1650, 2012

DOI: 10.2217/pgs.12.147

Links

Tools

Export citation

Search in Google Scholar

miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?

Journal article published in 2012 by Eva Dreussi, Paola Biason ORCID, Giuseppe Toffoli, Erika Cecchin
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

In recent years pharmacogenomic research has highlighted several genetic biomarkers of treatment toxicity and efficacy, dealing with drug metabolism, transport and mechanism of action. More recently, polymorphisms in miRNA encoding genes, their targets or factors involved in their maturation are rising as new pharmacogenomic markers in cancer. miRNAs are brief ncRNAs involved in DNA translational control, with an effect on mRNA and protein-expression levels. The study of genetic polymorphisms in genes involved in miRNA translational control machinery could give innovative insights in pharmacogenomics. This review summarizes the most recent and promising results in the field and gives an overview of the future perspective of personalized cancer therapy.